What are the indications, dosing recommendations, contraindications, and common adverse effects of cefuroxime?

Cefuroxime: Clinical Overview

Cefuroxime is a second-generation cephalosporin antibiotic effective against common respiratory, urinary, skin, and soft tissue infections, with proven activity against beta-lactamase-producing organisms including Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus. 1

Indications

Cefuroxime is indicated for infections caused by susceptible bacteria across multiple organ systems:

Respiratory Tract Infections

• Community-acquired pneumonia (CAP): Cefuroxime 1.5 g IV three times daily is recommended for hospitalized patients with non-severe pneumonia requiring parenteral therapy 2. For severe pneumonia, it should be combined with a macrolide (erythromycin 500 mg IV four times daily or clarithromycin 500 mg IV twice daily) 2.
• Acute bacterial rhinosinusitis: Oral cefuroxime axetil 500 mg twice daily for 10 days is an acceptable option for adults with mild disease and no recent antibiotic use (calculated clinical efficacy 85%, bacteriologic efficacy 88%) 3. For children, cefuroxime axetil 30 mg/kg/day in 2 divided doses (maximum 500 mg per dose) is recommended 3.
• Acute exacerbations of chronic bronchitis: Oral formulation effective for non-pneumonic bronchial complications 2.

Early Lyme Disease

Cefuroxime axetil 500 mg twice daily for 14-21 days is a first-line option for adults with early localized or disseminated Lyme disease with erythema migrans 4. For children, the dose is 30 mg/kg/day in 2 divided doses (maximum 500 mg per dose) 4.

Urinary Tract Infections

Cefuroxime demonstrates excellent urinary concentration. A single daily dose of 250 mg for 10 days achieved 86% cure rate in acute uncomplicated UTI 5. The drug achieves PTA of 100% for MIC values up to 8 mg/L in urinary tract infections 6.

Skin and Soft Tissue Infections

Cefuroxime axetil 250 mg twice daily for 10 days is effective for cutaneous infections, achieving 92% clinically beneficial outcomes 7.

Intra-abdominal Infections

Cefuroxime 1.5 g IV three times daily is an acceptable option for complicated intra-abdominal infections in adults 8. For children, 20-30 mg/kg IV three times daily 8.

Pediatric Considerations

For children with CAP, cefuroxime is recommended when local epidemiology documents high-level penicillin resistance in invasive S. pneumoniae 9.

Dosing Recommendations

Adults

Oral (Cefuroxime Axetil):

• Standard infections: 250-500 mg twice daily for 10-14 days 10, 11
• Respiratory infections: 500 mg twice daily 12
• Lyme disease: 500 mg twice daily for 14-21 days 4
• Uncomplicated gonorrhea: 1 g single dose 11

Intravenous:

• Moderate infections: 750 mg every 8 hours 2
• Severe infections/pneumonia: 1.5 g every 8 hours 2, 8
• Intra-abdominal infections: 1.5 g every 8 hours 8

Pediatric Dosing

Oral (Cefuroxime Axetil):

• 1-24 months: 125 mg twice daily 2
• 2-12 years: 250 mg twice daily 2
• General dosing: 30 mg/kg/day in 2 divided doses (maximum 500 mg per dose) 9, 3

Intravenous:

• 20-30 mg/kg three times daily 2
• CAP: 150 mg/kg/day every 8 hours 9

Sequential IV-to-Oral Therapy

For CAP, IV cefuroxime 750 mg 2-3 times daily for 2-5 days followed by oral cefuroxime axetil 500 mg twice daily for 3-8 days is effective 10. Switch to oral therapy should occur as soon as clinically appropriate 2.

Renal Adjustment

Dosage reduction required for impaired renal function 1. Seizures have been reported in patients with renal impairment when dosage was not reduced 1.

Pharmacokinetic Considerations

• Bioavailability: Oral tablets achieve 68% absolute bioavailability (range 63-73%) when taken with food 11
• Peak concentrations: 250 mg oral yields 4.6 mg/L; 500 mg yields 7.9 mg/L 11
• Protein binding: 33% 11
• Excretion: Predominantly unchanged in urine, making it highly effective for UTIs 6, 5
• Target attainment: Tablet doses of 250 mg and 500 mg twice daily achieve target T>MIC (40%) and PTA (≥90%) for MICs up to 0.25 and 0.5 mg/L respectively 6. Oral suspension covers MICs up to 1.0 mg/L due to superior absorption 6.

Contraindications

Cefuroxime is absolutely contraindicated in patients with known allergy to the cephalosporin group of antibiotics 1.

Important Caveats

• First-generation cephalosporins (e.g., cephalexin) are ineffective for Lyme disease and should not be used 4
• Doxycycline is contraindicated in pregnancy, lactation, and children <8 years; cefuroxime is a safe alternative in these populations 4
• For β-lactam allergic patients with Type I hypersensitivity reactions, cefuroxime should be avoided; alternatives include fluoroquinolones or macrolides 3

Adverse Effects

Common (Mild to Moderate)

• Gastrointestinal: Diarrhea (1 in 220 patients), nausea (1 in 440 patients), vomiting 1, 10
• Local reactions: Thrombophlebitis with IV administration (1 in 60 patients) 1
• Dermatologic: Rash (1 in 125 patients), pruritus, urticaria 1

Less Common

• Hematologic: Decreased hemoglobin/hematocrit (1 in 10 patients), transient eosinophilia (1 in 14 patients), neutropenia (<1 in 100), leukopenia (1 in 750), rare thrombocytopenia 1
• Hepatic: Transient elevation in SGOT/SGPT (1 in 25), alkaline phosphatase (1 in 50), LDH (1 in 75), bilirubin (1 in 500) 1
• Renal: Elevations in serum creatinine and BUN 1
• Gynecologic: Candida vaginitis (8% in UTI study) 5

Serious (Rare)

• Hypersensitivity: Anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, angioedema, cutaneous vasculitis 1
• Neurologic: Seizures, particularly in patients with renal impairment when dosage not reduced 1
• Cardiovascular: Acute myocardial ischemia with or without infarction as part of allergic reaction 1
• Gastrointestinal: Pseudomembranous colitis (may occur during or after treatment) 1
• Hematologic: Positive Coombs' test, aplastic anemia, hemolytic anemia, hemorrhage 1
• Other: Interstitial nephritis, drug fever 1

Management of Adverse Effects

• Most adverse events are mild to moderate and reversible upon discontinuation 10
• If seizures occur, discontinue drug immediately; anticonvulsant therapy may be indicated 1
• Monitor for pseudomembranous colitis during and after treatment 1

Comparative Tolerability

Adverse event rates are generally comparable to other cephalosporins and β-lactam antibiotics. In comparative trials, cefuroxime showed similar or better tolerability than cefaclor, amoxicillin/clavulanate, and macrolides 10, 7.